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Invited commentary
Kudos to Professor Edward Towpik, M.D., Ph.D., Edi-
tor-In-Chief of Nowotwory, for taking on the “IF-Mania”. I was 
impressed by his comprehensive and thorough review of 
the relevant scientific literature. I am also grateful for his 
invitation to address the growing controversy on what the 
JIF should represent, and how it evolved. Below are some of 
my (personal) thoughts, based on over 35-year experience of 
working as a physician-scientist, first at Harvard University, 
Boston (1979–1997) and then at the University of California, 
Los Angeles (1997–present).
First, to set up the stage, we need to recognize that IF 
was conceived by Eugene Garfield to evaluate science and 
social science journals per se [1]. However, IF became a meas-
ure and symbol of the scientific prestige and relevance, while 
all comparisons were supposed to include journals rather 
than individuals. It soon became clear that only journals 
dedicated to the same scientific specialty must be com-
pared because the value of the IF varies greatly between the 
disciplines. As an example from my own field, the IF of the 
most “prestigious” surgical journal, Annals of Surgery, equals 
8.327, versus IF of 21.561 attached to the “best” immunology 
journal, Immunity. More, if you are a plastic surgeon, the 
IF of a top journal you dream of publishing your research, 
Plastic and Reconstructive Surgery, is 2.993. Can we really 
compare “apples and oranges”? I have no doubt that impact 
factors are important for journal’s editors, and I happen to 
be one of them (Current Opinion in Organ Transplantation; 
IF = 2.880). However, the idea that impact factors in any way 
reflect the quality or reliability of the science, or the ability 
and creativity of a scientist, may be misleading. On the 
other hand, most esteemed journals, such as New England 
Journal of Medicine (IF = 55.873); Lancet (IF = 45.217) or An-
nual Reviews in Immunology (IF = 39.327) have always been 
and most likely will remain top science journals for years to 
come. I tend to believe, against the critiques, that a journal 
with high reputation is an appropriate (or even preferable) 
vehicle to assist a scientist, especially a young one, in expo-
sure of his or her research. Certainly, there are plenty of high 
impact papers that are published in low-impact journals 
and vice-versa. Most important is to publish good quality 
and innovative science and to have a record of continuous 
publications and productivity.  
Another example, from my field, is of a brilliant scientist 
who may suffer a “heart attack” by focusing his publication 
choices solely at JIF. In 2010, many high quality manuscripts 
were submitted for publication in Cell Transplantation, 
IF = 6.204. One year later, the journal had been dropped from 
Journal Citation Reports (JCR) and had no IF at all (current 
IF = 3.127). Obviously, those who published high quality pa-
pers in 2010 in Cell Transplantation (and other journals where 
IF changed drastically) were in total loss in 2011. Needless 
to say, IF-mania associating the value of research with the 
journal where the work is published, may distort the way 
science is conducted. Moreover, JIFs are often influenced by 
positive feedbacks with citations not based on the reading 
the paper itself but by reading other papers, primarily re-
views. Some even claim that there is a “positive” correlation 
between the rate of paper retraction and JIF. 
According to Eugene Garfield, out of 38 million articles 
published from 1900 to 2005, half were never cited, whereas 
only 0.5% was cited more than 200 times [2]. For good or 
for bad, citations are important as they reflect as to whether 
and how published science resonates and moves the field 
forward. Let’s be honest, there is a lot of bad science around, 
which should have never been published, at the first place. 
In the last 20 years or so, the citation fishing and cita-
tion-bartering became major pursuits on both sides of the 
Atlantic. Based on my observations, I do believe the perni-
cious effects of IF-mania are benign as compared to the 
European scene. As a Vice-Chair for Research in the Depart-
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ment of Surgery at UCLA, the largest solid organ transplant 
center in the country, I keep my mind open that I am not 
hiring or evaluating a “number” but a person with a mix 
of abilities, of which, in the research field, the originality 
is the most important. The question then arises whether 
“originality” can be measured by the JIF or past citations? 
In the current economic climate, with shrinking federal 
research budget and NIH grant success at all-time low of 
about 10%, we do need “metrics” to objectively evaluate 
grant applications. This is a demanding and frustrating task 
as the process may affect many careers. Obviously, innova-
tive research plan, supported by solid preliminary data, is 
of utmost importance for the ultimate success. However, 
we, the reviewers need also to look carefully where the ap-
plicant comes from, i.e., what is his/her publication record. 
Clearly, papers published in “top-tier” journals will impress 
and make the proposal more legitimate as compared with 
publications in low impact or no IF journals. It’s worth men-
tioning that the most recent NIH bio-sketch revision requires 
the applicant to outline up to five his/her research areas of 
the highest “scientific impact”. On a personal note, when 
I started my career at Harvard in the early 1980s, obviously 
“happy days” with no JIFs around, Transplantation, was our 
journal. Now, the very same journal (IF = 3.802) is one of 
many to attract our research. Needless to say, in the revised 
NIH bio-sketch, and despite many subsequent contributions 
in much higher IF journals, I do cite Transplantation papers 
from the 1980s on lymphocyte trafficking as one of the most 
impactful in my career.
Let me conclude by stating that high impact (factor) 
research became hot commodity that pays… First, we have 
too many journals, which charge too much for publish-
ing scientific data. The higher IF of the journal, the steeper 
publication costs. Are you willing to spend over $2,000 for 
5 color prints and page charges to publish a paper in Gas-
troenterology (IF = 16.716)? I did and have to admit I was 
very pleased to do so, despite the price tag and months of 
hard work to address reviewers’ critique. To make the long 
story short, that paper has led to the second and the third 
one (published in JIF of 10–12), ultimately resulting in NIH 
funding. I doubt I were equally successful if my research 
was published, for instance in Journal of Surgical Research 
(IF = 1.936). Obviously, the review process in a “prestigious” 
high impact factor journal is not trivial. It is a grueling ex-
perience as you are dealing with the highest caliber of your 
own, in most cases honest but tough, peers. 
Pursuing research career nowadays (i.e., in the IF-mania 
era) is not easy, but let’s be realistic, IFs do influence the 
reputation of researchers and will influence their careers 
for years to come. Perhaps, H-index, which measures the 
total number of papers a scientist has authored and the 
number of citations those papers have received, may be 
more acceptable to some. If, over a lifetime of a research 
career, you have authored 50 papers that have been cited 
50 or more times, your H-index = 50. This measure should 
satisfy most of malcontents, as it relates to the papers, which 
are cited over years, even if published in journals with low 
IF. The bottom line is, you need to publish research that is 
reproducible, impactful and moves your field forward. And 
remember, you have to impress your peers to read your 
publications and cite your discoveries!
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